IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: With these wide-ranging effects, IFN-α has been employed in numerous clinical trials for the treatment of a variety of solid tumors, as well as hematologic malignancies, such as hairy cell leukemia and chronic myeloid leukemia [38].